Salvage treatment strategies for ipsilateral breast tumor recurrence after breast-conserving therapy: a real-world study
The Oncologist · 06.08.2026 · 31 (9)
DOI: 10.1093/oncolo/oyag274 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 27.07.2026. Verfasst von Shenkangle Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, China. Hauptthemen laut MEDLINE: Salvage Therapy, Mastectomy, Segmental, Neoplasm Recurrence, Local, Breast Neoplasms. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Salvage mastectomy has long been regarded as the standard treatment for ipsilateral breast tumor recurrence (IBTR) after initial breast-conserving surgery (BCS) combined with radiotherapy. However, the feasibility and oncological outcomes of alternative local treatment strategies—such as repeat BCS (R-BCS) with or without re-irradiation, or mastectomy combined with re-irradiation—remain unclear. Materials and methods Using data from the Surveillance, Epidemiology, and End Results (SEER) database, we retrospectively analyzed female patients who developed IBTR after initial BCS combined with radiotherapy. Overall survival (OS), breast cancer–specific survival (BCSS), cumulative incidence of second IBTR, and cumulative incidence of contralateral breast cancer were compared between patients treated with salvage mastectomy and those receiving alternative local treatment strategies.
Results
A total of 4651 patients were included. After propensity score matching (PSM), all three groups—R-BCS alone, R-BCS with re-irradiation, and mastectomy with re-irradiation—showed comparable OS, BCSS and contralateral breast cancer risk when compared with salvage mastectomy as the reference. Compared with mastectomy alone, the cumulative incidence of 10-year second IBTR was significantly higher in the R-BCS-alone group (0.36% vs 5.04%, P = .002), while no significant differences were observed for R-BCS combined with re-irradiation or mastectomy combined with re-irradiation (P > .999 and P = .305, respectively). Subgroup analyses suggested that re-irradiation might correlate with inferior survival in triple-negative IBTR.
Conclusion
For patients experiencing recurrence after breast-conserving therapy, R-BCS combined with re-irradiation represents a viable alternative to salvage mastectomy. R-BCS alone may increase the risk of second IBTR, while the addition of re-irradiation to mastectomy did not provide additional benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, China.
- Zhejiang Key Laboratory of Biotherapy, Hangzhou, Zhejiang 310016, China.
- Department of Radiation Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, China.
- Department of Surgical Oncology, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang 317000, China.
- Department of General Surgery, The Ninth People's Hospital of Hangzhou, Hangzhou, Zhejiang 310014, China.
- Department of Breast and Thyroid Surgery, The People's Hospital of Ningguo, Xuancheng, Anhui 242300, China.
ORCID-Profile: Shenkangle Wang, Ziyu Zhu, Zijie Guo, Jichun Zhou
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, S., Zhu, Z., Cui, B., Lin, X., Guo, Z., Wu, Q., Xu, X., Sun, X., & Zhou, J. (2026). Salvage treatment strategies for ipsilateral breast tumor recurrence after breast-conserving therapy: a real-world study. The Oncologist, 31(9). https://doi.org/10.1093/oncolo/oyag274
Vancouver
Wang S, Zhu Z, Cui B, Lin X, Guo Z, Wu Q, et al. Salvage treatment strategies for ipsilateral breast tumor recurrence after breast-conserving therapy: a real-world study. The Oncologist. 2026;31(9). doi:10.1093/oncolo/oyag274
BibTeX
@article{Wang2026,
author = {Wang, Shenkangle and Zhu, Ziyu and Cui, Binbin and Lin, Xixi and Guo, Zijie and Wu, Qingliang and Xu, Xianjun and Sun, Xiaonan and Zhou, Jichun},
title = {Salvage treatment strategies for ipsilateral breast tumor recurrence after breast-conserving therapy: a real-world study},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {9},
doi = {10.1093/oncolo/oyag274}
}
EUVIMED